• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    R

    Retina Vitreous Associates of Florida

    企业EST. 1971
    113论文总数
    2,730引用总数

    论文量&引用量时间轴

    机构学者

    论文(113)

    年份
    起
    –
    止
    排序
    1Rapid Fluid Resolution and Durability with Faricimab in Neovascular Age-Related Macular Degeneration
    John D Pitcher, Adrian Hock Chuan Koh,Colin S Tan, Priya Vakharia, Nicholas Dagincourt,Shriji Patel,Ming Yang,Philippe Margaron,Roberto Gallego-Pinazo

    Importance:In the TENAYA and LUCERNE randomized clinical trials (RCTs), approximately 80% of study participants with treatment-naive neovascular age-related macular degeneration (nAMD) achieved at least every-12-week faricimab dosing at week 112. Subsequent post hoc analyses showed more rapid drying with faricimab compared with aflibercept, 2 mg, during the initial head-to-head dosing phase (weeks 0-12). Objective:To investigate whether rapid drying with faricimab, specifically intraretinal fluid (IRF) and subretinal fluid (SRF) resolution through week 12, is associated with later treatment durability. Design, Setting, and Participants:This is a post hoc analysis of faricimab-treated study participants from the TENAYA and LUCERNE RCTs, which were randomized, double-masked, multicenter, noninferiority studies of the efficacy and safety of faricimab, 6 mg, up to every 16 weeks vs aflibercept, 2 mg, every 8 weeks. Study participants in this post hoc analysis were those who had treatment-naive nAMD and were in the faricimab arm of TENAYA and LUCERNE. Data analysis was performed from July 2024 to December 2025. Intervention:Faricimab, 6 mg, up to every 16 weeks after 4 loading doses (received once every 4 weeks). Following disease activity assessments at week 20 or 24, participants received fixed dosing up to every 16 weeks until week 60 and then a treat-and-extend-based dosing regimen. Main Outcomes and Measures:Multinomial logistic regression modeling was used to test the association between resolution of IRF and SRF through week 12 and the faricimab treatment interval at week 20 or 24 (the first opportunity to extend treatment intervals) and at week 112 (study completion). Results:This analysis included 552 participants with their dosing interval at week 20 or 24 available (265 participants with IRF and SRF resolution and 287 without resolution); among them, 478 patients had their dosing interval at 112 weeks available (223 participants with IRF and SRF resolution and 255 without resolution). Study participants with IRF and SRF resolution through week 12, compared with those without resolution through week 12, were more likely to receive every-16-week dosing than every-8-week dosing (odds ratio [OR], 1.99; 95% CI, 1.23-3.21; P = .005) and to receive every-12-week dosing than every-8-week dosing (OR, 1.77; 95% CI, 1.09-2.87; P = .02) at week 20 or 24, and they were more likely to receive every-16-week dosing than every-8-week dosing at week 112 (OR, 1.76; 95% CI, 1.10-2.83; P = .02). Conclusions and Relevance:These findings suggest that rapid fluid resolution through week 12 with faricimab may be a predictor of extended durability (dosing intervals of every 12 weeks or longer) in participants with nAMD. Trial Registration:ClinicalTrials.gov Identifiers: NCT03823287 and NCT03823300.

    2026JAMA ophthalmology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2Variables Associated with Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration
    Colin S. Tan,Benjamin Bakall, Adrian Hock Chuan Koh, Priya Vakharia, Deepak Sambhara,Mathias Maier,Quresh Mohamed,Ming Yang,Philippe Margaron,Shriji Patel,Eric H. Souied

    This post hoc analysis of 2 randomized clinical trials evaluates baseline and early treatment response factors associated with longer faricimab dosing intervals in patients with neovascular age-related macular degeneration.

    2026JAMA Ophthalmology(2026)
    引用
    AI阅读
    加入学术空间
    3Aflibercept 2 Mg Biosimilar (Aflibercept-Ayyh, Pavblu): Experience of Safety in Clinical Settings-Apex- Safety Study.
    Ashish Sharma,Arshad M Khanani,David Eichenbaum, David Boyer, Alexander Shaer, Trisha Ortiz, Humza Sulahria, Allyza Flores,Carl Regillo, and the Inter BIOS Group
    2026Eye (London, England)(2026)
    引用
    AI阅读
    加入学术空间
    4Retinal Fluid, Thickness, and Leakage in PDS-treated Study Eyes Vs Intravitreal Injection-Treated Fellow Eyes in Bilateral DME in the Pagoda Trial
    Yi-Ting Hsieh,David Aaron Eichenbaum,Jordan Graff,Jason Hsu,Patricia Udaondo, Robert Wirthlin,Ashwini Bobbala,Shamika Gune,Dominic Heinrich, Melissa Kaye Jones, Amy Lin
    2026INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2026)
    引用
    AI阅读
    加入学术空间
    5Subretinal Sura-vec Maintains or Improves Vision (BCVA) and Retinal Thickness (CRT) in Subjects with Neovascular Age-Related Macular Degeneration: A Time in Range Analysis
    Mark Barakat,Dante Joseph Pieramici,David Aaron Eichenbaum, Peter A. Campochiaro,Stephen M. Huddleston,Arshad M. Khanani,Amber Lewis,Masara Issa,Mila Malhotra, Runzhi Zhang, Kevin Gleason, Kevin Zheng,
    2026INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 113 篇论文

    合作机构(100)

    基因泰克合作论文 13
    再生元製藥合作论文 7
    Ophthalmic Consultants of Boston合作论文 7
    波恩大学合作论文 6
    Palmetto Retina Center合作论文 6
    杜克大学合作论文 6
    California Retina Consultants合作论文 5
    Tennessee Retina合作论文 5
    加利福尼亚大学洛杉矶分校合作论文 4
    Midwest Eye Institute合作论文 4

    机构统计